PMID- 24848755
OWN - NLM
STAT- MEDLINE
DCOM- 20150615
LR  - 20220316
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 74
IP  - 8
DP  - 2014 Jun
TI  - Tofogliflozin: first global approval.
PG  - 939-44
LID - 10.1007/s40265-014-0229-1 [doi]
AB  - Tofogliflozin (Apleway((R)), Deberza((R)) [Japan]), an orally active small molecule 
      sodium-glucose co-transporter type 2 (SGLT2) inhibitor, has been developed by 
      Chugai Pharmaceutical for the treatment of type 2 diabetes mellitus (T2DM), and a 
      marketing authorization application was filed in Japan in 2013 by licensees 
      Sanofi K.K. and Kowa. Tofogliflozin has received its first global approval for 
      this indication in Japan as either monotherapy or in combination with other 
      antihyperglcaemic agents. This article summarizes the milestones in the 
      development of tofogliflozin leading to this first approval for the treatment of 
      T2DM.
FAU - Poole, Raewyn M
AU  - Poole RM
AD  - Adis, Auckland, New Zealand.
FAU - Prossler, Jennifer E
AU  - Prossler JE
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - P8DD8KX4O4 
      (6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol)
SB  - IM
MH  - Animals
MH  - Benzhydryl Compounds/administration & dosage/pharmacology/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Drug Approval
MH  - Drug Therapy, Combination
MH  - Glucosides/administration & dosage/pharmacology/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Japan
MH  - Sodium-Glucose Transporter 2 Inhibitors
EDAT- 2014/05/23 06:00
MHDA- 2015/06/16 06:00
CRDT- 2014/05/23 06:00
PHST- 2014/05/23 06:00 [entrez]
PHST- 2014/05/23 06:00 [pubmed]
PHST- 2015/06/16 06:00 [medline]
AID - 10.1007/s40265-014-0229-1 [doi]
PST - ppublish
SO  - Drugs. 2014 Jun;74(8):939-44. doi: 10.1007/s40265-014-0229-1.